Aquestive Therapeutics (AQST) Amortization of Deferred Charges (2017 - 2026)

Aquestive Therapeutics' Amortization of Deferred Charges history runs 10 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Amortization of Deferred Charges fell 16.87% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was -$221000.0, a 170.61% decrease from a year earlier, with the FY2025 full-year figure at $243000.0, up 2.97% from the prior year.
• Amortization of Deferred Charges improved to $2.3 million in Q1 2026 per AQST's latest filing, from $62000.0 in the prior quarter.
• Across five years, Amortization of Deferred Charges topped out at $2.8 million in Q1 2025 and bottomed at -$7.8 million in Q4 2024.
• The 5-year median for Amortization of Deferred Charges is $61000.0 (2025), against an average of $285294.1.
• Biggest YoY gain for Amortization of Deferred Charges was 89000.0% in 2024; the steepest drop was 544.01% in 2024.
• Year by year, Amortization of Deferred Charges stood at $58000.0 in 2022, then soared by 2920.69% to $1.8 million in 2023, then slumped by 544.01% to -$7.8 million in 2024, then surged by 100.8% to $62000.0 in 2025, then soared by 3587.1% to $2.3 million in 2026.
• Per Business Quant, the three latest AQST Amortization of Deferred Charges figures stand at $2.3 million (Q1 2026), $62000.0 (Q4 2025), and $61000.0 (Q3 2025).